Literature DB >> 21115559

Resveratrol commonly displays hormesis: occurrence and biomedical significance.

Edward J Calabrese1, Mark P Mattson, Vittorio Calabrese.   

Abstract

Resveratrol induces hormetic dose responses in a wide range of biological models, affecting numerous endpoints of biomedical and therapeutic significance. These responses were reported for numerous human tumor cell lines affecting breast, prostate, colon, lung, uterine and leukemia. In such cases, low concentrations of resveratrol enhanced tumor cell proliferation whereas higher concentrations were inhibitory. Similar resveratrol-induced biphasic dose responses were seen with several parasitic diseases, including Leishmaniasis and trichinella. Hormetic effects were also reported in animal models for cardiovascular induced injury, gastric lesions, ischemic stroke, Alzheimer's disease and osteoporosis. In these cases, there was often a protective effect at low doses but an adverse effect at higher doses, exacerbating the disease process/incidence. This analysis indicates that many effects induced by resveratrol are dependent on dose and that opposite effects occur at low and high doses, being indicative of a hormetic dose response. Despite consistent occurrence of hormetic dose responses of resveratrol in a wide range of biomedical models, epidemiologic and clinical trials are needed to assess the nature of its dose-response in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115559     DOI: 10.1177/0960327110383625

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  54 in total

1.  3,4',5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency.

Authors:  Fahad S Aldawsari; Carlos A Velázquez-Martínez
Journal:  Invest New Drugs       Date:  2015-02-28       Impact factor: 3.850

Review 2.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 3.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

4.  Challenges of translating basic research into therapeutics: resveratrol as an example.

Authors:  James M Smoliga; Ole Vang; Joseph A Baur
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-07-11       Impact factor: 6.053

5.  Advances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public Health.

Authors:  Iris R Bell; Gary E Schwartz; Nancy N Boyer; Mary Koithan; Audrey J Brooks
Journal:  Eur J Integr Med       Date:  2013-04-01       Impact factor: 1.314

Review 6.  Neurohormetic phytochemicals: An evolutionary-bioenergetic perspective.

Authors:  Vikneswaran Murugaiyah; Mark P Mattson
Journal:  Neurochem Int       Date:  2015-04-07       Impact factor: 3.921

7.  Challenging oneself intermittently to improve health.

Authors:  Mark P Mattson
Journal:  Dose Response       Date:  2014-10-20       Impact factor: 2.658

Review 8.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Resveratrol and Alzheimer's Disease: Mechanistic Insights.

Authors:  Touqeer Ahmed; Sehrish Javed; Sana Javed; Ameema Tariq; Dunja Šamec; Silvia Tejada; Seyed Fazel Nabavi; Nady Braidy; Seyed Mohammad Nabavi
Journal:  Mol Neurobiol       Date:  2016-03-19       Impact factor: 5.590

10.  Resveratrol inhibits the proliferation of neural progenitor cells and hippocampal neurogenesis.

Authors:  Hee Ra Park; Kyoung Hye Kong; Byung Pal Yu; Mark P Mattson; Jaewon Lee
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.